CAJ | 학술논문

法匹拉韦(favipiravir)是由日本福山化学研制的一种RNA依赖的RNA聚合酶(RdRp)抑制剂类广谱抗病毒药物.2014年3月,在日本被批准用于新发或复发流感的治疗.目前,其在美国正在进行针对流感的III期临床研究.另外法匹拉韦对埃博拉病毒、西尼罗病毒、黄热病病毒、黄病毒、沙粒病毒、布尼亚病毒、甲病毒、肠道病毒和里夫特裂谷热病毒都有很好的体内或体外抗病毒作用,是一个很有前途的广谱抗病毒药物.笔者就法匹拉韦的基本信息、作用机制、药动学、药理药效等研发动态作一概述.
법필랍위(favipiravir)시유일본복산화학연제적일충RNA의뢰적RNA취합매(RdRp)억제제류엄보항병독약물.2014년3월,재일본피비준용우신발혹복발류감적치료.목전,기재미국정재진행침대류감적III기림상연구.령외법필랍위대애박랍병독、서니라병독、황열병병독、황병독、사립병독、포니아병독、갑병독、장도병독화리부특렬곡열병독도유흔호적체내혹체외항병독작용,시일개흔유전도적엄보항병독약물.필자취법필랍위적기본신식、작용궤제、약동학、약리약효등연발동태작일개술.
Favipiravir(trade name AVIGAN) is a broad spectrum antiviral drug, developed by Toyama Chemical of Japan, which selectively inhibits RNA-dependent RNA polymerase of RNA virus. In March 2014, Favipiravir was approved in Japan for the treatment of new or recurrent inlfuenza virus infection. Currently, one Phase Ⅲ clinical study of Favipiravir for the treatment of inlfuenza is being conducted in USA. Favipiravir is active against inlfuenza viruses, West Nile virus, yellow fever virus, lfavivirus, arenavirus, bunyaviruses, alphavirus, enteroviruses and Rift Valley fever virus. With its unique mechanism of action and broad range of antiviral activity, Favipiravir is a promising drug candidate for inlfuenza and many other RNA viral diseases. In this paper, we summarized data on its development history, chemical properties, mechanism of action, pharmacokinetics, pharmacodynamics, and clinical trials.